Innate Pharma collaborates with NCIC Clinical Trials Group on the phase I/II trial of IPH2201 in ovarian cancer
Annual results 2014: stronger cash position and expanded clinical portfolio
Number of shares and voting rights of Innate Pharma as at December 31, 2014
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
First Phase II trial with IPH2201 open in head and neck cancer
Enrollment closed to new patients in the Phase I trial investigating lirilumab in combination with ipilimumab
ASH 2014 : Lirilumab enhances Elotuzumab activity in preclinical models
Innate Pharma announces its financial calendar for 2015 as well as its participation in upcoming investor conferences
Financial information for the third quarter of 2014
IPH 4102 preclinical data published in “cancer research”
